Beyond The Molecule Fishawack Health

Emma Morris and Iain McGill uncover the fascinating story behind Quell Therapeutics, revealing how a team of 6 top scientists came together to develop a pioneering cell and gene therapy that harnesses the body's immune response to prevent life-threatening organ transplant rejection. In this episode, we cover the cutting-edge science, top trends in precision medicine, and what it takes to build a successful biotech in just 2 years.

Karen Petersen shares her inspiring story, mapping her journey from cancer survivor to founder of Karen's Club – a not-for-profit designed to support patients of color considering taking part in oncology clinical trials. She explores challenging topics, including building trust in marginalized communities, to reveal how life science companies can break down barriers to help patients participate in life-saving research.

Building a successful healthcare start-up takes tremendous amounts of time, knowledge, and funding – and new ventures face roadblocks at every turn. So, how do entrepreneurs navigate this incredibly complex market? Frank Jaskulke, Vice President of Intelligence at The Medical Alley Association, shares the lessons he’s learned and reveals how he is helping start-ups to scale, pivot, and build the social capital essential for winning in business and staying at the forefront of innovation.

Approximately 80% of clinical research and genomic studies consist of data from Caucasian participants. Roche and Genetech are determined to change that. Nicole Riche, Global Head of Health Equity and Population Science, reveals how her team developed a pioneering global strategy to address healthcare disparities across the entire product lifecycle to ensure the promise of personalized health care becomes a reality for all patients.

The rare disease diagnostic odyssey lasts on average 4.5 years. But what would happen if a novel innovation could diagnose a person with a rare disease instantaneously? Vanessa Lemarié, Director of Life Sciences Business Development and Program Owner of the Rare Disease Initiative at Ada Health, explains how the company is leveraging their ground-breaking medical AI technology to simplify diagnostic pathways and make the rare disease diagnostic odyssey a thing of the past.

The virtual clinical trial space exploded during the COVID-19 pandemic. So, what’s it like to be the CEO of a company skyrocketing at the center of the clinical trial revolution? We chat to Medable founder and CEO Michelle Longmire to explore how her global platform empowers clinicians to develop patient-centric research strategies. We uncover how she has coped with the rapid success that saw the company's revenue grow by more than 500% in 2020, and what the future holds for decentralized clinical trials and digital endpoints.